|
|
|
European Pharmaceutical Contractor
|
Bridging the Gap Between the Pharmaceutical and Preclinical CRO Industries
Pharmaceutical companies have traditionally outsourced a proportion of their preclinical development studies to contract research laboratories. This co-operation can be traced back to the mid-sixties and the proliferation of regulatory guidelines which followed the thalidomide disaster earlier that decade. At that time, the international requirements for protocol-driven toxicity studies for new pharmaceuticals put a strain on the resources of many drug companies.
The answer for many was to outsource individual studies to the rapidly-evolving contract research industry, pioneered by companies such as Huntingdon Research Centre in England and Inveresk Research in Scotland. These organisations turned their focus from experimental nutrition studies to the toxicity testing of drugs and other chemicals.
As the science of toxicology developed, so did the demands of the regulatory authorities, often resulting in inconsistencies between the various agencies. The introduction of Good Laboratory Practice (GLP) in 1978/9 also made it more difficult for some drug companies to perform studies themselves, adding further momentum to the growth of the CRO industry.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
2012 BIO International Convention
18-21 June 2012, Boston, Massachusetts
Connect, partner and innovate at the 2012 BIO International Convention, June 18-21, Boston, Mass. Network with 15,000+ global biotech leaders in the BIO Business Forum, Exhibition and Programme.
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
